Ofev FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved October 15, 2014)
Brand name: Ofev
Generic name: nintedanib
Dosage form: Capsules
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Treatment for: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
Ofev (nintedanib) is a small molecule tyrosine kinase inhibitor (TKI) indicated for:
- treatment of idiopathic pulmonary fibrosis (IPF).
- treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
- slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Development Timeline for Ofev
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.